Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest
It’s been a big day for Junshi Biosciences as it nabs China’s first snap approval for a homegrown PD-1 after reportedly closing a $394 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
